Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.
Heat Biologics, Inc is a biotechnology business based in the US. Heat Biologics shares (HTBX) are listed on the NASDAQ and all prices are listed in US Dollars. Heat Biologics employs 36 staff and has a trailing 12-month revenue of around USD$3.5 million.
|52-week range||USD$0.195 - USD$4.3|
|50-day moving average||USD$1.4406|
|200-day moving average||USD$1.073|
|Wall St. target price||USD$5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.654|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-09-17)||-100.00%|
|1 month (2020-08-27)||-100.00%|
|3 months (2020-06-26)||-100.00%|
|6 months (2020-03-26)||-100.00%|
|1 year (2019-09-26)||-100.00%|
|2 years (2018-09-26)||-100.00%|
|3 years (2017-09-26)||-100.00%|
|5 years (2015-09-25)||-100.00%|
|Revenue TTM||USD$3.5 million|
|Gross profit TTM||USD$-9,964,500|
|Return on assets TTM||-25.3%|
|Return on equity TTM||-59.43%|
|Market capitalisation||USD$194.7 million|
TTM: trailing 12 months
There are currently 7.8 million Heat Biologics shares held short by investors – that's known as Heat Biologics's "short interest". This figure is 53% up from 5.1 million last month.
There are a few different ways that this level of interest in shorting Heat Biologics shares can be evaluated.
Heat Biologics's "short interest ratio" (SIR) is the quantity of Heat Biologics shares currently shorted divided by the average quantity of Heat Biologics shares traded daily (recently around 18.2 million). Heat Biologics's SIR currently stands at 0.43. In other words for every 100,000 Heat Biologics shares traded daily on the market, roughly 430 shares are currently held short.
However Heat Biologics's short interest can also be evaluated against the total number of Heat Biologics shares, or, against the total number of tradable Heat Biologics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Heat Biologics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Heat Biologics shares in existence, roughly 50 shares are currently held short) or 0.0515% of the tradable shares (for every 100,000 tradable Heat Biologics shares, roughly 52 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Heat Biologics.
Find out more about how you can short Heat Biologics stock.
We're not expecting Heat Biologics to pay a dividend over the next 12 months.
Heat Biologics's shares were split on a 1:10 basis on 22 January 2018. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Heat Biologics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Heat Biologics shares which in turn could have impacted Heat Biologics's share price.
Over the last 12 months, Heat Biologics's shares have ranged in value from as little as $0.195 up to $4.3. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Heat Biologics's is 0.4331. This would suggest that Heat Biologics's shares are less volatile than average (for this exchange).
Heat Biologics, Inc., a biopharmaceutical company, focuses on developing immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. The company's T-cell activation platform, includes two variations for intradermal administration, such as immune pan-antigen cytotoxic therapy, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and combination pan-antigen cytotoxic therapy, a dual-acting immunotherapy, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. It is developing HS-110, which is in phase II clinical trials to treat patients with advanced non-small cell lung cancer. The company's preclinical stage products include HS-130 for the treatment of advanced solid tumors; PTX-35, a humanized affinity matured monoclonal antibody, which is a functional agonist of human TNFRSF25 signaling; and PTX-45, a human TL1A-Ig fusion protein that acts as an agonist of TNFRSF25 signaling. Heat Biologics, Inc. has collaboration with Waisman Biomanufacturing to manufacture COVID-19 Vaccine. The company was founded in 2008 and is headquartered in Morrisville, North Carolina.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.